Clinically significant induction interactions, all 2014 NMEs as victims
| Victim Drug (Dose) | Inducer (Dose) | Enzymes /Transporters Possibly Involved | Max AUC Ratio | Max Cmax Ratio | Study Design/Populationa | Labeling Impact | Reference |
|---|---|---|---|---|---|---|---|
| Eliglustat (100 mg twice daily for 6 d) | Rifampin (600 mg once daily for 6 d) | CYP3A | 0.04 | 0.05 | One-sequence/6 healthy subjects (CYP2D6 PMs) | Y | FDA, 2014e |
| Naloxegol (25 mg SD) | Rifampin (600 mg once daily for 10 d) | CYP3A, P-gp | 0.11 | 0.26 | One-sequence/22 healthy subjects | Y | FDA, 2014t |
| Olaparib (300 mg SD) | Rifampin (600 mg once daily for 13 d) | CYP3A | 0.11 | 0.30 | One-sequence/17 patients with advanced solid tumors | Y | FDA, 2014s |
| Suvorexant (40 mg SD) | Rifampin (600 mg once daily for 17 d) | CYP3A | 0.12 | 0.36 | One-sequence/10 healthy subjects | Y | FDA, 2014c |
| Tasimelteon (20 mg SD) | Rifampin (600 mg once daily for 11 d) | CYP1A2, CYP3A, CYP2C9, CYP2C19 | 0.14 | 0.23 | One-sequence/24 healthy subjects | Y | FDA, 2014l |
| Netupitant (300 mg SD) | Rifampin (600 mg once daily for 17 d) | CYP3A | 0.20 | 0.45 | Random Crossover/18 healthy subjects | Y | FDA, 2014a |
| Idelalisib (150 mg SD) | Rifampin (600 mg once daily for 8 d) | CYP3A, P-gp | 0.24 | 0.43 | One-sequence/11 healthy subjects | Y | FDA, 2014an |
| Apremilast (30 mg SD) | Rifampin (600 mg once daily for 15 d) | CYP3A, P-gp | 0.28 | 0.57 | One-sequence/21 healthy subjects | Y | FDA, 2014aa |
| Paritaprevir (150 mg SD) | Carbamazepine (200 mg once daily for 3 d, twice daily for 21 d) | CYP3A, P-gp | 0.30 | 0.44 | One-sequence/12 healthy subjects | Y | FDA, 2014ai |
| Dasabuvir (250 mg SD) | Carbamazepine (200 mg once daily for 3 d, twice daily for 21 d) | CYP3A, P-gp | 0.30 | 0.46 | One-sequence/12 healthy subjects | Y | FDA, 2014ai |
| Ceritinib (750 mg SD) | Rifampin (600 mg once daily for 14 d) | CYP3A | 0.30 | 0.56 | One-sequence/19 healthy subjects | Y | FDA, 2014ao |
| Ledipasvir (90 mg SD) | Rifampin (600 mg once daily for 7 d) | P-gp | 0.40 | 0.69 | One-sequence/31 healthy subjects | Y | FDA, 2014k |
| Vorapaxar (2.5 mg once daily for 22 d) | Rifampin (600 mg once daily for 28 d) | CYP3A | 0.45 | 0.61 | Parallel, placebo-controlled/12 healthy subjects | Y | FDA, 2014am |
| Pirfenidone (801 mg SD) | Cigarette smoking (dose not provided) | CYP1A2 | 0.49 | 0.71 | Parallel/healthy subjects (26 smokers and 25 nonsmokers) | Y | FDA, 2014i |
| Nintedanib (150 mg SD) | Rifampin (600 mg once daily for 7 d) | CYP3A, P-gp | 0.50 | 0.60 | One-sequence/25 healthy males | Y | FDA, 2014x |
Maximum AUC and Cmax ratios of the victim drugs are presented.
↵a The number of subjects listed represents the number of subjects who completed the study, as described in the DIDB.